INVO Bioscience Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016	2015
Net Income	-8.03	-10.89	-6.65	-8.35	-2.17	-3.08	-0.7	-2.12	-4.96
Depreciation & Amortization	0.2	0.08	0.17	0.03	0.03	0.01	0	0	0.01
Share-Based Compensation	1.29	2.22	1.9	1.61	0.09	0	0	1.26	0.09
Other Operating Activities	1.79	1.99	-1.45	1.93	3.43	2.42	0.52	0.53	4.71
Operating Cash Flow	-4.76	-6.6	-6.03	-4.78	1.37	-0.65	-0.18	-0.32	-0.15
Capital Expenditures	-0.44	-0.01	-0.45	-0.09	-0.06	-0.02	0	-0.02	0
Acquisitions	-2.05	-0.07	-1.7	-0.1	0	0	0	0	0
Other Investing Activities	-	-	-	-0	-0.05	-	-	-	-
Investing Cash Flow	-2.49	-0.08	-2.15	-0.19	-0.11	-0.02	0	-0.02	0
Share Issuance / Repurchase	5.7	0.29	3.9	11.48	0	0.08	0.05	0	0.65
Debt Issued / Paid	1.66	0.8	-0.25	2.35	-0.23	0.78	0	0	-0.02
Other Financing Activities	0.02	-	0.12	-	-	-	-	-	-
Financing Cash Flow	7.39	1.09	3.77	13.82	-0.23	0.86	0.05	0	0.63
Net Cash Flow	0.14	-5.59	-4.41	8.86	1.03	0.19	-0.13	-0.34	0.47
Free Cash Flow	-5.2	-6.62	-6.48	-4.86	1.31	-0.67	-0.18	-0.34	-0.15
Free Cash Flow Margin	-172.15%	-804.68%	-155.87%	-468.92%	88.21%	-136.00%	-64.25%	-667.18%	-1297.13%
Free Cash Flow Per Share	-3.32	-10.91	-12.20	-17.72	5.38	-2.92	-0.82	-1.56	-0.76

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).